Patents Assigned to Array Biopharma Inc.
  • POLYMORPHS OF ARRY-380, A SELECTIVE HER2 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20230241066
    Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.
    Type: Application
    Filed: January 3, 2023
    Publication date: August 3, 2023
    Applicant: Array BioPharma Inc.
    Inventors: Donald T. Corson, Christopher M. Lindemann, Daniel J. Watson
  • TREATMENT OF BRAIN CANCER
    Publication number: 20230190749
    Abstract: Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 22, 2023
    Applicant: Array BioPharma Inc.
    Inventors: Patrice A. Lee, Shannon L. Winski, Kevin Koch
  • Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Patent number: 11648243
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: May 16, 2023
    Assignee: Array Biopharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, James Collier, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. Mcfaddin, Megan L. Mckenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Ginelle A. Ramann, Tony P. Tang, Li Ren, Shane M. Walls
  • N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
    Publication number: 20230142839
    Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
    Type: Application
    Filed: September 8, 2022
    Publication date: May 11, 2023
    Applicant: Array BioPharma Inc.
    Inventors: Joseph P. LYSSIKATOS, Julie Marie HICKS, Fredrik P. MARMSATER, Qian ZHAO
  • Compounds for the treatment of BRAF-associated diseases and disorders
    Patent number: 11634409
    Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
    Type: Grant
    Filed: May 16, 2022
    Date of Patent: April 25, 2023
    Assignee: Array BioPharma Inc.
    Inventors: Patrick Michael Barbour, Katie Keaton Brown, Adam Wade Cook, Erik James Hicken, Dean Russell Kahn, Ellen Ruth Laird, Andrew Terrance Metcalf, David Austin Moreno, Bradley Jon Newhouse, Spencer Phillip Pajk, Brett Joseph Prigaro, Li Ren, Eugene Tarlton
  • Protein tyrosine phosphatase inhibitors
    Patent number: 11634417
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: April 25, 2023
    Assignee: Array BioPharma Inc.
    Inventors: James F. Blake, Mark Laurence Boys, Mark Joseph Chicarelli, Adam W. Cook, Mohamed S. A. Elsayed, Jay Bradford Fell, John P. Fischer, Ronald Jay Hinklin, Yutong Jiang, Oren T. McNulty, Macedonio J. Mejia, Martha E. Rodriguez, Christina E. Wong
  • METHODS TO TREAT CANCER USING (R)-N-(3-FLUORO-4-((3-((1-HYDROXYPROPAN-2-YL)AMINO)-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)OXY)PHENYL)-3-(4-FLUOROPHENYL)-1-ISOPROPYL-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE
    Publication number: 20230117328
    Abstract: This invention relates to a method of treating cancer by administering to a patient in need thereof, over a period of time, therapeutic agents that comprises Compound 1 or a pharmaceutically acceptable salt thereof on an intermittent dosing schedule alone or in combination with a PD-1 or PD-L1 inhibitor, to a patient in need thereof.
    Type: Application
    Filed: March 1, 2021
    Publication date: April 20, 2023
    Applicant: Array BioPharma Inc.
    Inventors: Karyn Sue BOUHANA, Jim Yuk-Fai WONG
  • SOLID DISPERSIONS OF A ERB2 (HER2) INHIBITOR
    Publication number: 20230097309
    Abstract: A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein. Also, a pharmaceutical composition comprising a solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and uses thereof are provided herein.
    Type: Application
    Filed: August 25, 2022
    Publication date: March 30, 2023
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: David Shank Fry, Christopher M. Lindemann, Michael Preigh, Corey Jay Bloom, Christopher Donovan Craig, Devon Brevard Dubose, Jeff Gautschi, Dan Smithey
  • Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
    Patent number: 11603374
    Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: March 14, 2023
    Assignee: Array BioPharma Inc.
    Inventors: James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Andrew T. Metcalf, David A. Moreno, Brett Prigaro, Ginelle A. Ramann, Li Ren
  • HER2 MUTATION INHIBITORS
    Publication number: 20230041385
    Abstract: This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L2, R1, R2, R3, R4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
    Type: Application
    Filed: June 25, 2022
    Publication date: February 9, 2023
    Applicant: Array BioPharma Inc.
    Inventors: Bryan Daniel ELLIS, Erik James HICKEN, Ellen Ruth LAIRD, Nicholas Charles LAZZARA, Bradley Jon NEWHOUSE, Spencer Phillip PAJK, Rachel Zoe Rosen, Russell Andrew Shelp
  • Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them
    Patent number: 11571424
    Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: February 7, 2023
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: Donald T. Corson, Christopher M. Lindemann, Daniel J. Watson
  • HER2 MUTATION INHIBITORS
    Publication number: 20230023851
    Abstract: This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
    Type: Application
    Filed: June 29, 2021
    Publication date: January 26, 2023
    Applicant: Array BioPharma Inc.
    Inventors: Mark Laurence BOYS, Bryan Daniel ELLIS, John Joseph GAUDINO, Erik James HICKEN, Ellen Ruth LAIRD, Nicholas Charles LAZZARA, Bradley Jon NEWHOUSE, Spencer Phillip PAJK
  • PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES
    Publication number: 20230011441
    Abstract: Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.
    Type: Application
    Filed: July 15, 2021
    Publication date: January 12, 2023
    Applicant: Array BioPharma Inc.
    Inventors: Ronald Jay Hinklin, Shelley Allen, Patrick Barbour, Adam Cook, Joshua Dahlke, John Gaudino, Ellen Laird, Oren T. McNulty, Qian Zhao
  • KRas G12C inhibitors
    Patent number: 11548888
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: January 10, 2023
    Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: Matthew Arnold Marx, James Gail Christensen, Christopher Ronald Smith, John P Fischer, Aaron Craig Burns
  • Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
    Patent number: 11524963
    Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1 and R2 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: December 13, 2022
    Assignee: Array Biopharma Inc.
    Inventors: James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Brett Prigaro, Li Ren
  • Treatment of brain cancer
    Patent number: 11504370
    Abstract: Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: November 22, 2022
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: Patrice A. Lee, Shannon L. Winski, Kevin Koch
  • Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
    Patent number: 11472802
    Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: October 18, 2022
    Assignee: Array BioPharma Inc.
    Inventors: Shane M. Walls, Li Ren, Ginelle A. Ramann, David A. Moreno, Andrew T. Metcalf, Elizabeth A. McFaddin, Gabrielle R. Kolakowski, James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Dean Kahn
  • KRas G12D inhibitors
    Patent number: 11453683
    Abstract: Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: September 27, 2022
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P. A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS
    Publication number: 20220288074
    Abstract: Provided herein is a compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors.
    Type: Application
    Filed: June 4, 2021
    Publication date: September 15, 2022
    Applicant: Array BioPharma Inc.
    Inventors: Patrick Michael DOERNER BARBOUR, Tanna Marie BETTENDORF, Dean Russell KAHN, Alex Andrew KELLUM, Ellen Ruth LAIRD, David Austin MORENO, Li REN
  • Compounds and compositions as protein kinase inhibitors
    Patent number: RE49556
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: June 20, 2023
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie